Specialty Care Biostatistics, Pfizer Inc., New York, NY, USA.
J Eval Clin Pract. 2013 Aug;19(4):579-83. doi: 10.1111/j.1365-2753.2011.01802.x. Epub 2011 Nov 29.
Despite their inherently pervasive limitations, data from observational studies are increasingly relied upon by health care decision makers to fill critical information gaps created by lack of evidence from randomized controlled trials.
The aim and objective of this article was to revisit the major issues associated with observational studies from secondary data sources.
The method of this article was canvass of the literature.
Sources of bias are highlighted and steps intended to minimize bias are summarized.
Efforts should be made to improve causal inference of treatment effects from observational studies found in secondary data sources. Extra care and caution should be exercised in the interpretation and reporting of results from these studies.
尽管观察性研究存在固有的局限性,但医疗保健决策者越来越依赖这些研究的数据来填补随机对照试验缺乏证据造成的关键信息空白。
本文的目的和目标是重新审视次要数据来源的观察性研究相关的主要问题。
本文的方法是对文献进行综述。
强调了偏倚的来源,并总结了旨在最小化偏倚的步骤。
应努力提高从次要数据来源中观察性研究中治疗效果的因果推断。在解释和报告这些研究的结果时,应格外小心谨慎。